Treatment with bisphosphonates to mitigate calcification of elastin-containing bioprosthetic materials

Treatment with bisphosphonates to mitigate calcification of elastin-containing bioprosthetic materials Full article

Journal

Journal of Biomedical Materials Research - Part A
ISSN: 1549-3296

Output data

Year: 2020, Volume: 108, Number: 7, Pages: 1579-1588 Pages count : 10 DOI: 10.1002/jbm.a.36927

Tags

bioprosthetic calcification; bisphosphonic acid; bovine jugular vein; cross-linking; porcine aortic wall

Authors

Zhuravleva Irina Y. ¹ , Polienko Yuliya F. ² , Karpova Elena V. ² , Timchenko Tatyana P. ¹ , Vasilieva Maria B. ¹ , Baratova Ludmila A. ³ , Shatskaya Svetlana S. ⁴ , Kuznetsova Elena V. ¹ , Nichay Nataliya R. ¹ , Beshchasna Natalia ⁵ , Bogachev-Prokophiev Alexander V. ¹

Affiliations

1	(Scopus) Center for Innovative Surgical Technologies, E. Meshalkin National Medical Research Center of the RF Ministry of Health, Novosibirsk, Russian Federation
2	(Scopus) Laboratory of Nitrogen Compounds (Y.F. Polienko) and Center of Spectral Research (E.V.Karpova), N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Novosibirsk, Russian Federation
3	(Scopus) Department of chromatographical analysis, A. Belozersky Research Institute of Physico-Chemical Biology MSU, Moscow, Russian Federation
4	(Scopus) Laboratory of Intercalation and Mechanochemical Reactions, Institute of Solid State Chemistry and Mechanochemistry SB RAS, Novosibirsk, Russian Federation
5	(Scopus) Bio- and Nanotechnology Department, Fraunhofer Institute for Ceramic Technologies and Systems, Dresden, Germany

This study evaluated the ability of bisphosphonates (BPAs) of different molecular structures to mitigate the calcification of porcine aortic wall (PAW) and bovine jugular vein wall (BJVW). Tissues cross-linked with glutaraldehyde (GA) or diepoxide (DE) were modified with pamidronic acid (PAM), alendronic acid (ALE), neridronic acid (NER) (type 1 BPAs); 2-(2′-carboxyethylamino)ethylidene-1,1-bisphosphonic acid (CEABA), 2-(5-carboxypentylamino)ethylidene-1,1-bisphosphonic acid (CPABA) (type 2); and zoledronic acid (ZOL) (type 3). After implanting the tissue samples subcutaneously in 100 rats, calcification was examined using atomic absorption spectrophotometry (60-day explants) and light microscopy after von Kossa staining (10- and 30-day explants). The calcium contents in GA-BJVW and GA- and DE-PAW increased up to 100–120 mg/g after 60 days, while being 3 times lower in DE-BJVW. In modified and nonmodified PAW samples, calcium phosphates appeared by day 10 and were associated with elastic fibers and devitalized cellular elements. In all groups of BJVW samples, mineralization began in elastic fibers near the subendothelial layer. In addition, calcified collagen was found in the GA-BJVW samples. Minimal calcification was found in GA-PAW treated with type 1 BPAs and CEABA. For DE-PAW and GA-BJVW, the calcium level significantly decreased with PAM and CEABA. Meanwhile, ALE and NER were effective for DE-BJVW. © 2020 Wiley Periodicals, Inc.

Zhuravleva I.Y. , Polienko Y.F. , Karpova E.V. , Timchenko T.P. , Vasilieva M.B. , Baratova L.A. , Shatskaya S.S. , Kuznetsova E.V. , Nichay N.R. , Beshchasna N. , Bogachev-Prokophiev A.V.
Treatment with bisphosphonates to mitigate calcification of elastin-containing bioprosthetic materials
Journal of Biomedical Materials Research - Part A. 2020. V.108. N7. P.1579-1588. DOI: 10.1002/jbm.a.36927 WOS Scopus

Published online:	Apr 9, 2020
Published print:	Jul 1, 2020

Web of science	WOS:000530109500012
Scopus	2-s2.0-85083058944
OpenAlex	W3010762012